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Changes in Cerebral Glucose Metabolism in
Patients with Parkinson Disease with Dementia
After Cholinesterase Inhibitor Therapy
Phil Hyu Lee*1, Seok Woo Yong*2, and Young-Sil An3
1Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea; 2Department of Neurology, Ajou University
School of Medicine, Suwon, South Korea; and 3Department of Nuclear Medicine, Kyung Hee University School of Medicine, Seoul,
South Korea
We investigated changes in cerebral glucose metabolism after
cholinesterase inhibitor (ChEI) therapy in patients with Parkinson
disease dementia (PDD) to determine whether cognitive im-
provements would be reflected in changes of cerebral metabolic
patterns, thus offering insight into the neural substrate of cogni-
tive dysfunction in patients with PDD.Methods:Weperformed a
serial PET study before (baseline) and after ChEI therapy on 10
patients with PDD, using statistical parametric mapping. Addi-
tionally, covariance analysis was performed to extract regions
in which increased change in regional cerebral metabolism cor-
related significantly with increased Mini-Mental State Exam-
ination scores. Results: The statistical parametric mapping
analysis indicated that significantly increased cerebral metabo-
lism after ChEI therapy, comparedwith at baseline, wasmost ev-
ident in the left angular gyrus extending to the supramarginal
area and left superior and middle frontal gyri. Additionally, cere-
bral metabolism was significantly increased in the right superior
frontal and left middle orbitofrontal gyri. In contrast, the right fu-
siform gyrus showed significantly decreased metabolism after
ChEI, compared with at baseline. In the correlation analysis, im-
provements in Mini-Mental State Examination scores after ChEI
treatment were significantly associated with increased cerebral
metabolism in the left supramarginal, orbitofrontal, and cingulate
areas.Conclusion:Our data suggest that prefrontal and parietal
association areas may be relevant structures for the pharmaco-
logic response to ChEI in patients with PDD.
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Cognitive dysfunction occurs in 25%230% of patients
with Parkinson disease (PD); this prevalence is 6 times
greater than that among the population in general (1–3). The
key feature of dementia in PD is executive dysfunction; thus,
patients with PD dementia (PDD) have difficulty in tasks that
require generation of mental sets, planning, and cognitive
sequencing. Additionally, patients with PDD often exhib-
ited worse performance in visuospatial tasks and memory
impairment in free recalls, which improved significantlywith
external cues, suggesting that these patients still had the
ability to store new information (3,4).
Although the exact pathophysiologic substrate in PDD is
still controversial, progressive involvement of subcortical
and cortical structures, by Lewy-type pathology or Alz-
heimer disease–like histologic changes, has been suggested
(5,6). Regarding neurochemical substrates in PDD, recent
pathologic and functional studies have suggested that cho-
linergic deficits were significantly correlated with cognitive
dysfunction in patients with PD (7–9). Various kinds of
cholinesterase inhibitors (ChEIs), including rivastigmine
(10), donepezil (11), and galantamine (12), have proven to
be effective in improving cognitive function in patients with
PDD, supporting this theory.
Only 1 study, which used SPECT, reported that ChEIs
significantly increased cerebral perfusion in frontal and
cingulate areas (13). However, images obtained with PET
have much greater spatial resolution and attenuation correc-
tion than those obtained with SPECT. A study comparing
PETand SPECT images in patients with dementiawith Lewy
bodies (DLB) showed the superiority of PET in demonstrat-
ing regional effects in cerebral metabolism (14). In the
current study, we performed a serial PET study analysis
before and after ChEI therapy in patients with PDD.We used
statistical parametric mapping (SPM) to evaluate whether
cognitive improvements were reflected in cerebral metabo-
lism after ChEI therapy, thus offering insight into the neural
substrate of cognitive dysfunction in patients with PDD.
MATERIALS AND METHODS
Subjects
Participants were recruited consecutively from a university
hospital outpatient clinic. We prospectively enrolled 12 patients
with a clinical diagnosis of PDD. PD was determined according to
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the clinical diagnostic criteria of the UK Parkinson’s Disease
Society Brain Bank (15). PDD was diagnosed when the patient
had dementia due to PD, according to the DSM-IV criteria (16).
Patients who developed dementia more than 1 y after the onset of
parkinsonian motor symptoms, according to the 1-y rule between
the onset of dementia and parkinsonism (17), were included in the
study. The severity of dementia was assessed using the Mini-
Mental State Examination (MMSE). Exclusion criteria included
evidence of focal brain lesions by MRI, the presence of other
neurodegenerative diseases that may account for the dementia, and
prior use of a ChEI or anticholinergic drug. Possible medical
comorbidities were also excluded by laboratory tests, including a
thyroid function test, vitamin B12 and folic acid level assessment,
and a venereal disease research laboratory test.
All patients with PDD underwent a cardiac 123I-metaiodoben-
zylguanidine (123I-MIBG) scan to possibly exclude other conditions
of parkinsonism. Patients were treated with donepezil, starting at
5 mg daily for 4 wk, which was increased to 10 mg daily. Of 12
patients initially diagnosed with PDD, 2 were excluded in this
analysis; one could not tolerate donepezil; and was treated with
galantamine, and the other had the delayed heart-to-mediastinum
ratio that did not lie more than 2 SDs below the normal mean of our
hospital (18). The mean delayed cardiac 123I-MIBG uptake in
patients with PDD included in this study was 1.23. All subjects
gave informed consent to the study, and the trial was approved by
the Institutional Review Board for Human Investigation of Ajou
University Hospital, Suwon, South Korea.
18F-FDG PET Data Acquisition
In all subjects, the first PET scan was performed before ChEI
therapy; the second PET scan was performed when patients had
been treated with ChEI therapy for longer than 3 mo. PET/CT data
were acquired on a Discovery ST scanner (GE Healthcare). Dopa-
minergic medications were discontinued for more than 12 h before
the PET scan. After fasting for at least 4 h, patients received 300
MBq of 18F-FDG intravenously. We checked serum glucose levels
in all subjects before the 18F-FDG injection; subjects whose glucose
level exceeded 150 mg/dL were excluded. All subjects were
instructed to rest comfortably for 30 min with their eyes closed
and ears unplugged, and then image acquisition was started. To
reduce head movement during scanning, patients were positioned
and maintained using an individually molded head holder. Patients
first underwent aCT scan (tube rotation time, 1 s/revolution; 120 kV;
70 mA; 5.0 mm/rotation; acquisition time, 11.8 s; scan length,
150.42 mm). Subsequently, emission PET data (1 frame, 8 min/
frame) were acquired in 3-dimensional mode. PET images were
reconstructed by iterative reconstruction (ordered-subsets expecta-
tion maximization, with 1 iteration and 32 subsets), using the CT
images for attenuation correction. The randoms correction by
singles and model-based scatter correction was also applied.
Data Analysis
18F-FDG PET images were spatially normalized to a standard
template provided by SPM2 (Institute of Neurology, University of
London) in MATLAB (version 7.1; Mathworks Inc.). A local op-
timization of the 12 parameters of an affine transformation was
applied to the spatial normalization. The images were then smoothed
with a gaussian kernel (full width at half maximum, 16 mm) to
minimize noise and improve between-subject spatial alignment.
To identify brain regions in which metabolic activity had changed
after ChEI therapy, baseline and follow-up PET images were
compared voxel by voxel (2-tailed paired t test), and an uncor-
rected P value of less than 0.005 was considered significant.
Additionally, covariance analysis was performed to extract regions
in which increased changes in regional cerebral metabolism were
significantly correlated with the increase in MMSE scores, using a
single-subject covariate model. Regions reaching an uncorrected P
value of less than 0.05 were considered significant in the covari-
ance analyses. Anatomic labeling of significant voxels was per-
formed using the automated anatomic labeling SPM toolbox (19),
which was based on anatomy provided by the Montreal Neuro-
logic Institute.
Statistical Analysis
A Wilcoxon paired signed rank test was used to compare the
changes in MMSE scores after ChEI therapy; P values of less than
0.05 were deemed statistically significant. Statistical analyses
were performed using commercially available software (SPSS,
version 13.0; SPSS Inc.).
RESULTS
The characteristics of the patients are summarized in
Table 1. Data are mean 6 SD. The mean age of the patients
was 74.7 6 4.5 y. The mean disease durations of PD and
PDD were 6.4 6 4.2 y (range, 2–14 y) and 8.4 6 6.4 mo
TABLE 1
Demographic Characteristics in Patients with PDD
Patient no. Sex Age (y)
Dopaminergic
drug (mg)
PD
duration (y)
Dementia
duration (mo)
First
MMSE
Second
MMSE
1 M 81 L 600/R 6 14 4 15 21
2 F 78 L 450 5 24 22 19
3 M 75 L 600 3 6 16 18
4 F 68 L 450/E 600 3 3 21 29
5 F 67 L 450 2 5 20 25
6 F 77 L 600/E 800 10 3 16 27
7 M 78 L 600/E 800 3 6 19 23
8 F 77 L 450 10 9 17 22
9 M 73 L 450/E 600 4 12 23 25
10 M 73 L 700/E 800 10 12 22 30
L 5 levodopa; R 5 ropinirole; E 5 entacapone.
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(range, 3–24 mo), respectively. The mean stage of Hoehn
and Yahr was 3.1 6 0.4. The mean duration of education
was 6.6 6 5.3 y. Two patients were current smokers. The
mean interval between the first and second PET scans was
3.56 0.3 mo. The mean MMSE score at baseline was 19.16
2.9 (range, 15–23). After ChEI therapy (mean treatment
duration, 3.5 mo), a significant improvement was observed
in MMSE scores (23.96 4.0; mean change, 4.8 points; P5
0.012). In analyzing the change of subitems of MMSE
before and after ChEI therapy, serial sevens and delayed
recall subitems were significantly improved after ChEI
treatment (each mean change of score, 1.0 and 1.4, respec-
tively; each P 5 0.04 and 0.01, respectively). The regis-
tration subitem was marginally improved (mean change of
score, 0.5; P5 0.09). However, no significant improvement
in other subitems of time orientation (0.7 points), place
orientation (0.4 points), language (0.8 points), and penta-
gon copy (0 point) was demonstrated.
The SPM analysis showed that significantly increased
cerebral metabolism after ChEI therapy, compared with at
baseline, wasmost evident in the left angular gyrus extending
to the supramarginal gyrus and superior and middle frontal
gyri (Puncorrected, 0.001). Additionally, cerebralmetabolism
was significantly increased in the right superior frontal and
left middle orbitofrontal gyri (Puncorrected , 0.005; Fig. 1;
Table 2). In contrast, the right fusiform gyrus showed sig-
nificantly decreased cerebral metabolism after ChEI therapy,
compared with baseline (Puncorrected , 0.001; Fig. 2; Table
2). In the correlation analysis between changes in cerebral
metabolism and MMSE scores, improved MMSE scores
after ChEI treatment were significantly associated with
increased cerebral metabolism in the left supramarginal, left
orbitofrontal, and left cingulate cortices (Puncorrected, 0.05,
Fig. 3; Table 3).
DISCUSSION
Previous postmortem and in vivo studies demonstrated
that cholinergic activity in patients with PDD was pro-
foundly lowered in the cerebral cortex, showing more
severe cholinergic dysfunction in patients with PDD than
in patients with Alzheimer disease (AD) (8,20,21). With
patients with AD, there were reports about the effects of
both short-term and long-term treatment of ChEI on the
change of cerebral metabolism (22–24); however, no study
has reported on changes in cerebral metabolic patterns after
ChEI use in patients with PDD. In this study, we evaluated
the cerebral metabolic pattern before and after ChEI treat-
ment and correlated cerebral metabolism with cognitive
improvement using SPM analysis. We demonstrated that
cognitive function as measured by MMSE scores signifi-
cantly improved after the introduction of ChEIs, compared
with at baseline, and cerebral metabolism increased signif-
icantly in the prefrontal and left parietal association areas.
In a correlation analysis involving the change in cerebral
metabolism and MMSE scores, cognitive improvement after
ChEI therapy was significantly associated with increased
cerebral metabolism in the left supramarginal, orbitofrontal,
and cingulate cortices.
In our study, the cortical area showing increased metab-
olism after ChEI treatment was consistent with regions of
decreased cholinergic activity in patients with PDD, com-
paredwith thosewith PD.Hilker et al. (25), in an invivo study
using N-11C-methyl-4-piperidyl, an acetylcholine analog,
reported that regional acetylcholine esterase activity signif-
icantly decreased in the parietal and limbic areas in patients
with PDD, compared with those with PD without dementia.
Furthermore, the increased metabolic area after ChEI treat-
ment is consistent with the cortical area showing decreased
perfusion or metabolism in PDD. Firbank et al. (26) demon-
strated that patients with PDD showed more perfusion
deficits in the lateral parietal association area than did
patients who had PD without dementia. Recently, in a study
of metabolic patterns using SPM analysis, we demonstrated
that patients with PDD, compared with patients with PD,
showed patterns of decreased metabolism in the bilateral
inferior andmedial frontal lobes and in the right parietal lobe
(27). For the correlation of cognitive status with choline
acetyltransferase activity and cerebral perfusion in patients
with PDD, choline acetyltransferase activity in the prefrontal
cortex and cerebral perfusion in the parietal cortex had a
significant negative correlation with cognitive impairment
(7). Additionally, several studies have demonstrated that
ChEI treatment significantly improved attentional, execu-
tive, and visuospatial functions (3,28), suggesting a potential
role for ChEIs in refining control in frontal and parietal
function. Although the MMSE is not sensitive in detecting
executive and visuospatial functions, cognitive improvement
after ChEI in our study seems to be related to attention-
mediatedMMSE subitems (serial sevens, delayed recall, and,
partially, registration). Our data, showing increased metab-
olism in the prefrontal and left parietal association areas and a
significant correlation between changes in metabolism and
cognitive improvement, suggest that these areas may be
relevant structures for the pharmacologic response to ChEI
therapy in PDD. Our results relate to findings that the degree
of cerebral metabolism was significantly correlated with
acetylcholine esterase activity in patientswith dementia (29).
FIGURE 1. Statistical pa-
rametric maps showing
spatial distribution of signif-
icant metabolic increase af-
ter ChEI therapy in patients
with PDD.
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The metabolic or perfusion pattern in response to ChEI
therapy seems to be different between PDD and DLB. Mori
et al. (30) found that increased perfusion after ChEI treat-
ment in patients with DLBwas localized in the occipital area,
whereas a previous study by Ceravolo et al. (13) and our
current data showed that increased perfusion or metabolism
in patients with PDD was observed in the frontal or parietal
areas. Controversy still exists as to whether PDD and DLB
are indeed the same disease entities. The characteristics of
cognitive dysfunction and the pattern of metabolic derange-
ment are similar between the 2 conditions, although these
patterns tend to be more severe in DLB than in PDD. How-
ever, recent functional imaging and neuropathologic data
demonstrated that the burden of AD-like pathology and the
density of Lewy bodies are more severe in DLB than in PDD
(6,31,32), suggesting different pathologic backgrounds for
the 2 diseases. Thus, on the basis of our data and those of
another study, we speculate that at least the anatomic sub-
strate for the response to ChEIs in patients with PDDmay be
different from those with DLB, although this difference does
not directly indicate a different nature of disease between
PDD and DLB.
The increased metabolism in the frontal and parietal
regions after ChEI treatment in our study looks similar to
the short-term perfusion change pattern seen in response to
ChEIs in patients with AD, except for the metabolic or
perfusion changes in the temporal area (33,34). Because all
patients in this study had a lower cardiac MIBG uptake score
(in the PD range at our institute), and patients with AD are
known to have a reference range of cardiac MIBG uptake
(35), it is less likely that patients with AD would have been
included in our study. Nevertheless, without autopsy findings
it is impossible to exclude coexisting AD pathology in our
patients. In vivo imaging using 11C-PIB may be useful in
excluding coexisting AD pathology because PDD had a
lower burden of amyloid in the cortical area than didAD (32).
A possible explanation is that the restorative capacity ofChEI
therapy may focus particularly on attention and executive
functions by enhancing cholinergic neurotransmission in
certain areas of the frontal cortex, regardless of the underly-
ing pathologic process, thus resulting in similar changes in
functional images. However, this possibility is difficult to
reconcile with perfusion change localized in the occipital
area in patients with DLB. In addition to the pathologic status
of the nucleus basalis of Meynert, cortical cholinergic activ-
ity seems to be influenced by the type of protein aggregates
(20). Thus, a further direct comparative study regarding the
effect of ChEI therapy on changes in functional imaging
between patients with PDD, DLB, and AD would be needed
to clarify whether response patterns in functional imaging
after ChEI therapy are different with different pathologic
status.
Interestingly, a significantly decreased metabolism after
ChEI treatment in this study was localized in the fusiform
gyrus. It has been suggested that the fusiform gyrus is
strongly involved in the recognition of many different cate-
gories of objects and categoric encoding of complex visual
stimuli (36) and, thus, may contribute pathologically to vivid
and complex symptoms. Oishi et al. (37 ) compared perfusion
patterns between PD with and without visual hallucinations
and reported that dysfunction in the ventral pathway of the
visual recognition system, especially in the right fusiform
FIGURE 2. Statistical pa-
rametric maps showing spa-
tial distribution of significant
metabolic decrease after
ChEI therapy in patients with
PDD.
TABLE 2
Brain Area Showing Significant Change in Glucose Metabolism After ChEI Therapy in Patients with PDD
CoordinateGlucose
metabolism x y z Side Area
Voxel level
(Puncorrected)
Increased 250 254 28 Left Angular gyrus extending to supramarginal gyrus ,0.001
220 20 44 Left Superior and middle frontal gyrus ,0.001
226 54 24 Left Middle orbitofrontal gyrus ,0.005
18 40 36 Right Superior frontal gyrus ,0.005
Decreased 32 230 218 Right Fusiform gyrus extending to parahippocampal gyrus ,0.001
FIGURE 3. Statistical parametric maps showing correlation of
increased changes in regional cerebral metabolism and in-
crease of MMSE.
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gyrus, would be associated with visual processing dysfunc-
tion in PD. Mosimann et al. (38) reported the dissociation
between performance in object-form and space-motion per-
ception in patients with PDD, suggesting that visual percep-
tion associatedwith theventral visual pathwaywas profoundly
decreased. However, a decreased metabolism in the fusiform
gyrus is difficult to reconcile with previous reports that ChEI
improved visual hallucination in PDD (3,39). According to a
functional MRI study in patients with AD, cholinergic mod-
ulation on visual brain responses by ChEI seems to be region-
specific, depending on loss of functional cholinergic cortical
inputs. Bentley et al. (40) found that in patients with AD,
functionally impaired parahippocampal and precuneus re-
gions showed a stimulus-selectivity increase of blood oxy-
genation level–dependant (BOLD) signals after physostigmin,
whereas functionally intact fusiform cortex showed a decrease
of BOLD signals, as happened in the controls. Chronic
exposure to cholinesterase inhibitors may induce desensitiza-
tion of the acetylcholine receptor in the fusiform gyrus, a less
susceptible or functionally intact region in PDD, which leads
to decreased glucose metabolism in this area after ChEI
treatment.
Some limitations in our study need to be addressed. First,
the sample size is small, which may influence higher im-
provement of MMSE scores in our study, compared with
previous reports (10–12). Additionally, we could not analyze
the change in cerebral metabolism between patients with
cognitive improvement after ChEI treatment and those
without. Second, detailed neuropsychiatric evaluations are
lacking in this study, and although MMSE is a simple and
universally applied scale that can be easily and rapidly
performed by a clinician specializing in PDD (4), MMSE is
not sensitive in detecting cognitive impairments of the
frontoparietal subdomains. Therefore, we could not perform
a detailed correlation analysis between the change in cogni-
tive subdomains and cerebral metabolism.
CONCLUSION
We demonstrated that, compared with baseline, the intro-
duction of ChEIs in patients with PDD significantly in-
creased cerebral metabolism in the prefrontal and parietal
association areas. These regions were well correlated with
improvements in cognitive changes, as shown by MMSE
scores, suggesting that these areas may be relevant structures
for the pharmacologic response to ChEIs. A direct compar-
ative study,with a detailed neuropsychiatric evaluation in dif-
ferent groups with dementia, would be necessary to uncover
response patterns of cerebral metabolism in different demen-
tia disease groups and a correlation between the change in
cognitive subdomains and cerebral metabolism.
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